Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Health Minister Denies November Plan for Avigan's COVID-19 OK
October 7, 2020
-
BUSINESS Armed with Enerzair, Novartis Looks to Establish Leading Position in Respiratory Arena
October 6, 2020
-
REGULATORY MHLW to Draft Guidelines by Year-End on Use of Patient Registry Data in Drug Filing
October 5, 2020
-
BUSINESS AstraZeneca’s COVID-19 Vaccine Trial Resumes in Japan
October 5, 2020
-
BUSINESS Novartis’ Tabrecta Hits Snag in Japan on Hospitals’ CDx Reimbursement Issue
October 2, 2020
-
ACADEMIA Japanese Nephrology Society Publishes Recommendation on Use of HIF-PH Inhibitors
October 2, 2020
-
REGULATORY MHLW’s Review Division Head Stresses Evidence-Based Approval for Coronavirus Vaccines
October 1, 2020
-
REGULATORY Metformin Cancer Risk Acceptable at 1 in 550,000 Patients: NIHS Assessment
October 1, 2020
-
BUSINESS Torii Enjoys Stellar Performance from Corectim, 1st JAK Med for Atopic Dermatitis
September 30, 2020
-
BUSINESS Approval Now in Hand, CureApp Looks at Collaborations with Drug Makers to Push Therapeutic Apps
September 29, 2020
-
REGULATORY MHLW Approves Rakuten’s Photoimmunotherapy, Takeda’s PARP Inhibitor, Gilead’s Jyseleca and More
September 28, 2020
-
REGULATORY MHLW to Set Up Study Group to Investigate Formulary Initiatives at Hospitals: Pharmaceutical Management Director
September 25, 2020
-
BUSINESS LTL Pharma Looks to Acquire More Off-Patent Brands with Dellegra as a Catalyst
September 24, 2020
-
BUSINESS Avigan Hits Primary Goal for Novel Coronavirus, Filing Eyed in October: Fujifilm
September 24, 2020
-
BUSINESS Lucentis Biosimilar Filed in Japan; Senju/Gene Techno Eye 2021 Approval
September 23, 2020
-
REGULATORY Health Minister Vows to Gauge Impact on Medical Institutions in Discussing Off-Year Re-Pricing
September 18, 2020
-
REGULATORY New Japan PM Sticks to Abe’s Goal to Secure Coronavirus Vaccines for Whole Population by H1 2021
September 17, 2020
-
REGULATORY Ex-Health Minister Tamura Comes Back as MHLW Chief
September 16, 2020
-
REGULATORY Japan Inks COVAX Pact with Optional Arrangement, Commits 17.2 Billion Yen Upfront
September 16, 2020
-
BUSINESS Lilly Japan to Run Its First Voluntary Redundancy Program, 10% of Sales Force Targeted?
September 15, 2020
ページ
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…